Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer

BACKGROUND: Studies conducted in Swedish populations have shown that men with lowest prostate-specific antigen (PSA) levels at ages 44–50 years and 60 years have very low risk of future distant metastasis or death from prostate cancer. This study investigates benefits and harms of screening strategi...

Descripción completa

Detalles Bibliográficos
Autores principales: Heijnsdijk, Eveline A M, Gulati, Roman, Tsodikov, Alex, Lange, Jane M, Mariotto, Angela B, Vickers, Andrew J, Carlsson, Sigrid V, Etzioni, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566340/
https://www.ncbi.nlm.nih.gov/pubmed/32067047
http://dx.doi.org/10.1093/jnci/djaa001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566340/
https://www.ncbi.nlm.nih.gov/pubmed/32067047
http://dx.doi.org/10.1093/jnci/djaa001

Ejemplares similares